Screening for prostate cancer
125 results
1 - 100PSA screening for prostate cancer not recommended (USPSTF)
Ask-tell-ask approach to discussing prostate cancer screening
Prostate cancer screening increases harm risk without decreasing mortality
The full truth about prostate cancer screening is suppressed again (ERSPC)
MA: Low-quality evidence finds DRE screening for prostate cancer inaccurate
Have the USPSTF recommendations against screening caused more aggressive prostate cancer?
Prostate cancer screening: no mortality benefit after 15 years of follow-up (PLCO)
Prostate cancer screening: no mortality benefit after 13 years of follow-up (PLCO)
USPSTF 2018 recommends counseling 55 to 69-year-old men on benefits and harms of prostate cancer screening (C recommendation)
PSA screening does not decrease mortality
Better estimate of prostate cancer risk based on the number of close relatives with prostate cancer and their age at diagnosis
Low-intensity PSA-based screening does not reduce mortality, but leads to overdiagnosis and potential harm
ACP: Discuss prostate screening with men 50-69 years old
PSA screening does not reduce mortality from prostate CA (PLCO)
Need to screen 1055 and treat 37 to prevent one prostate CA death over 11 years (ERSPC)
PSA screening has marginal effect on mortality in European study (ERSPC)
Prediction model can decrease prostate biopsies in men with abnormal PSA
USPSTF: No PSA screening in men 75 years and older
Impact of PSA screening on quality of life
Modelling study shows less-intense screening is okay for men with low baseline PSA levels
Screening for ovarian cancer with CA-125/ultrasound algorithm does not reduce mortality (UKCTOCS)
PSA plus MRI-guided biopsy reduces the detection of clinically insignificant prostate cancers more than systematic biopsy
Screening CA-125 and transvaginal ultrasound does not reduce ovarian cancer mortality
For men with PSA > 3.0, limiting biopsy to lesions seen on MRI appears to be safe
Annual screening chest x-ray does not reduce lung cancer mortality
Observation = radical prostatectomy for most pts with localized prostate cancer (PIVOT)
Prostatectomy reduces mortality compared with no surveillance in men with T2 cancer who presented with symptoms
Treatment for symptom-detected early prostate CA effective in pts younger than 65